Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.
J. M. Jürgensmeier
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. M. Hoff
Consultant or Advisory Role - AstraZeneca
L. Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. D. Robertson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. Morgan
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
G. McWalter
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
D. Wilson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. C. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca